Vis-Rx
Payments companies reported to CMS as associated with Vis-Rx. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vis-Rx, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vis-Rx
These are the largest totals companies reported as associated with Vis-Rx. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Hiram Bezerra | Tampa, FL | Cardiovascular Disease | $285,268.25 |
| Eric Osborn | Boston, MA | Interventional Cardiology | $24,657.51 |
| Ryan Madder | Royal Oak, MI | Interventional Cardiology | $4,578.79 |
| Ricardo Hanel | Jacksonville, FL | Neurological Surgery | $2,002.79 |
| Matthew Price | La Jolla, CA | Interventional Cardiology | $1,642.56 |
| Timothy Henry | Cincinnati, OH | Interventional Cardiology | $723.64 |
| Evan Shlofmitz | Roslyn, NY | Interventional Cardiology | $699.84 |
| Craig Porter | Roslyn, NY | $270.57 | |
| Donald Quimby | Tampa, FL | Interventional Cardiology | $242.06 |
| Marc Feldman | San Antonio, TX | Interventional Cardiology | $235.95 |
Prescribed Vis-Rx?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.